Across TCGA pan-cancer cohorts, SRARP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SRARP data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SRARP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRARP expression acts as an unfavorable survival marker.

HNSC and LUSC are the cancer types where SRARP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.021	0.712	<.001	24	view →
LUSC	OS	Median	All	0.180	0.659	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SRARP tumor-vs-normal RNA expression · all SRARP data types